Clinically targeting oncogenic signaling pathways in breast cancer, such as those initiated by the estrogen receptor (ER) and the human epidermal growth factor receptor-2 (HER2), has been highly beneficial to the treatment of the disease. This evidence concerns the gene ESR1 and breast carcinoma.